BAM15 Capsules Canada — Capsules
Mitochondrial Uncoupler
BAM15 is a synthetic small-molecule mitochondrial protonophore studied in research for its capacity to uncouple oxidative phosphorylation.
🔬 This product is coming soon — ordering is not yet available.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
BAM15 is a synthetic small-molecule mitochondrial protonophore studied in research for its capacity to uncouple oxidative phosphorylation.
Experimental models examine its effect on mitochondrial membrane potential and cellular energy metabolism under controlled laboratory conditions.
Third-party tested for purity, ID, quantity.
Coming Soon
The certificate of analysis for this lot is being finalised and will be published here as soon as the lab returns it.
BAM15 is a mitochondrial uncoupler characterized for its ability to dissipate the proton gradient across the inner mitochondrial membrane without depolarizing the plasma membrane — a selectivity that has made it a tool compound in bioenergetics research.
Studies have evaluated its influence on metabolic rate, insulin sensitivity, and mitochondrial quality-control pathways in preclinical models.
BAM15 was identified during screening for mitochondrial protonophores with improved selectivity over earlier uncouplers such as 2,4-dinitrophenol. Its comparatively favorable profile in cell and animal models established it as a research probe for mitochondrial uncoupling.
Subsequent investigations expanded into metabolic, renal, and oncology research models.
Research into BAM15 centers on mitochondrial uncoupling and cellular energy-metabolism models. Frameworks evaluate membrane-potential dynamics, metabolic regulation, mitophagy, and oxidative signaling under controlled in vitro and preclinical conditions.
4 of the 4 areas below are addressed directly by a paper cited on this page.
Addressed on this page by Dantas 2022, Alexopoulos 2020, Xiong 2023. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Alexopoulos 2020, Dantas 2022. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Dantas 2022, Alexopoulos 2020, Xiong 2023. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Alexopoulos 2020. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
The references section of this page cites 3 primary papers published between 2020 and 2023 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
BAM15 Capsules is frequently listed as a peptide by suppliers in this market. It is not one. The structure published on this page is the compound's actual chemistry, and research on it should be read against its own class rather than against peptide literature.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for BAM15 Capsules, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
BAM15 Capsules is also referred to as BAM.
BAM15 Capsules is commonly described online in connection with weight loss, appetite suppression and fat reduction. In the research literature the same compound is filed under mitochondrial uncoupling models, energy-metabolism and obesity research and mitophagy and mitochondrial quality control.
The 3 papers cited on this page, published between 2020 and 2023 (1 in animal models) describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Every lot of BAM15 Capsules is independently assayed before it is released, and the certificate for the lot shipped is published rather than summarised. Where a certificate for a current lot is not yet posted, the lot has not yet been released against it.
Researchers who buy BAM15 Capsules in Canada through Eppix Labs receive a batch-labelled vial whose certificate is published against that lot code, so the material can be matched to its analysis rather than to a generic specification.
BAM15 Capsules is supplied in capsule form, which removes the reconstitution step entirely: there is no vehicle to add, no reconstitution volume to record and no post-reconstitution stability window to track. What that leaves a laboratory to control is storage — capsule shells draw moisture from the air, so the container should be kept sealed and dry rather than decanted into an open vessel.
Because the material is already at its labelled quantity per capsule, batch verification carries more weight in this format than it does for powder: there is no point at which the researcher independently confirms mass by weighing. The measured content published for each lot is the figure that answers that question.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of bam15. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice
PubMedBAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases
PubMedMitochondrial uncoupling attenuates sarcopenic obesity by enhancing skeletal muscle mitophagy and quality control
PubMedRelated
SalePeptides
Triple GIP / GLP-1 / Glucagon Agonist · 10, 20, 40 & 120 mg Retatrutide is a synthetic peptide developed for controlled laboratory research involving multi-receptor signaling systems. It is structurally designed to interact with GLP-1, GIP, and glucagon receptor pathways within experimental environments.
RETA-CA-26F-1099.637%
11.76 mg / 10 mg
$69.99$79.99CAD
Peptides
Dual GIP / GLP-1 Agonist · 10, 30 & 65 mg Tirzepatide is a synthetic peptide developed for controlled laboratory research involving dual incretin receptor signaling systems. It is structurally designed to interact with GLP-1 and GIP receptor pathways within experimental environments.
TIRZ-CA-26G-1099.634%
11.42 mg / 10 mg
$44.99CAD
SalePeptides
GLP-1 Receptor Agonist · 10 mg Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone involved in glucose-dependent signaling. It is developed for controlled laboratory investigation within regulated experimental environments.
10 mgSEMA-CA-26F-1099.504%
11.27 mg / 10 mg
$64.99$70.00CAD
SalePeptides
Selective Amylin Agonist (LY3841136) · 10 mg This product is supplied as eloralintide (LY3841136), a long-acting, selective amylin receptor agonist studied in research on metabolic and body-weight regulation.
10 mgELOR-CA-26G-1099.810%
12.42 mg / 10 mg
$119.99$150.00CAD
